logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer's Rheumatoid Arthritis Drug Xeljanz Gets Approval In Japan

Pharmaceutical giant Pfizer Inc. (PFE) Monday said the Japanese Ministry of Health, Labor and Welfare has approved Xeljanz for the treatment of adults with rheumatoid arthritis or RA who have had an inadequate response to existing therapies. The company added saying the drug may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate.

Xeljanz is expected to be initially made available in Japan to medical institutions participating in an all-patient surveillance program. The drug will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited.

The approval of Xeljanz in Japan is supported by a multi-study, global clinical development program, which evaluated the drug in approximately 5,000 patients across various RA patient populations.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cruise itineraries in the Caribbean islands are almost back to business after the hurricanes Irma and Maria blasted through some islands. The Florida-Caribbean Cruise Association announced on a press call Monday that the hardest hit major ports, St. Thomas and St. Croix in the U.S. Virgin Islands, and St. Maarten and San Juan, Puerto Rico, are expected to open by the end of November. Banking major Goldman Sachs Group Inc. (GS) reported Tuesday profit for the third-quarter that declined 3 percent from last year. But, quarterly net revenues increased 2 percent. Both earnings per share and revenues topped analysts' expectations. Weinstein Co. said it has entered into a preliminary agreement for immediate capital infusion from Colony Capital, the global private equity arm of Colony NorthStar, Inc. In addition, Weinstein Co. has entered into a negotiating period with Colony Capital for a potential sale of all or a significant portion of its assets. Further details of the deal were not disclosed.
comments powered by Disqus
Follow RTT